Loading…
Verrica Pharmaceuticals Inc. is projected to rise to $6.32 by 2027, a +1% move from its current price of $6.26. VRCA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.02 | $6.26 | $6.51 | -0.01% |
| Jul 14 | $5.93 | $6.26 | $6.61 | -0.02% |
| Jul 15 | $5.85 | $6.26 | $6.69 | -0.03% |
| Jul 16 | $5.79 | $6.26 | $6.76 | -0.04% |
| Jul 17 | $5.74 | $6.26 | $6.82 | -0.05% |
| Jul 18 | $5.69 | $6.26 | $6.88 | -0.06% |
| Jul 19 | $5.65 | $6.26 | $6.93 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.65 | $6.26 | $6.93 | -0.07% |
| Week 2 | $5.41 | $6.25 | $7.22 | -0.15% |
| Week 3 | $5.23 | $6.25 | $7.46 | -0.22% |
| Week 4 | $5.09 | $6.24 | $7.66 | -0.30% |
| Week 5 | $4.96 | $6.24 | $7.84 | -0.37% |
| Week 6 | $4.85 | $6.23 | $8.01 | -0.45% |
| Week 7 | $4.75 | $6.23 | $8.16 | -0.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company that develops and commercializes medications for the treatment of dermatologic diseases in the United States. Its portfolio includes YCANTH (VP-102), a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
Verrica was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. It has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications.
VRCA is Verrica Pharmaceuticals Inc., currently priced at $6.62 per share. The company has a market cap of $113.72M and is ranked 4145 by market capitalization.
The current price sits within a near-term context that combines technical support and resistance levels. The price action sits near a support level of $5.63 and a resistance level of $6.84, with a 30-day range of $5.08 to $8.63. The stock’s RSI is 60, and its 50-day simple moving average is $6.31 while the 200-day simple moving average is $5.99.
A major floor 30.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.1% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 34.7% above — clearing it would confirm fresh momentum.
Key VRCA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRCA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.32 | Sell | $6.33 | Sell |
| MA 10 | $6.31 | Sell | $6.26 | Buy |
| MA 20 | $6.08 | Buy | $6.18 | Buy |
| MA 50 | $6.30 | Sell | $6.16 | Buy |
| MA 100 | $6.00 | Buy | $6.18 | Buy |
| MA 200 | $6.00 | Buy | $6.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.68 | Neutral |
| Stoch RSI (14) | 43.91 | Neutral |
| CCI (20) | 46.10 | Neutral |
| Williams %R (14) | -48.33 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 10.80 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 51.67 | Neutral |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 0.29 | Buy |
| Ultimate (7,14,28) | 56.33 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 6.49 | Sell |
| ADX (14) | 9.46 | Neutral |
| ATR (14) | 0.23 | Info |
The 30-day technical picture is characterized by bullish sentiment, with RSI14 at 60. The 50-day SMA sits at $6.31 and the 200-day SMA at $5.99. Key support is at $5.63 and resistance at $6.84. The 30-day price range is $5.08 to $8.63.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.38 | $6.26 | $7.97 | 0% | Neutral | |
| $4.84 | $6.32 | $8.84 | +1% | Neutral | |
| $5.13 | $6.98 | $10.26 | +12% | Neutral | |
| $4.42 | $6.23 | $9.51 | 0% | Neutral | |
| $4.70 | $6.83 | $10.76 | +9% | Neutral | |
| $5.74 | $8.59 | $13.93 | +37% | Bullish | |
| $6.21 | $9.54 | $15.85 | +52% | Bullish | |
| $6.93 | $10.92 | $18.55 | +74% | Bullish | |
| $6.47 | $10.44 | $18.11 | +67% | Bullish | |
| $5.86 | $9.69 | $17.12 | +55% | Bullish | |
| $8.81 | $16.25 | $31.03 | +160% | Bullish | |
| $10.36 | $23.02 | $49.15 | +268% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.38 | $6.26 | $7.64 | +0.00% |
| August 2026 | $5.18 | $6.18 | $7.62 | -1.31% |
| September 2026 | $5.14 | $6.20 | $7.77 | +0.34% |
| October 2026 | $5.29 | $6.43 | $8.16 | +3.71% |
| November 2026 | $5.18 | $6.35 | $8.14 | -1.28% |
| December 2026 | $4.99 | $6.15 | $7.97 | -3.08% |
Click any year to see its month-by-month VRCA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VRCA price prediction for 2026 points to an average of $6.26 (low $4.38, high $7.97) — a potential gain of 0% on today's $6.26. A consolidation phase looks the most probable path here.
In 2027, VRCA is projected to trade between $4.84 and $8.84, averaging $6.32 — a potential gain of +1% from today's $6.26. That is up +1% on the projected 2026 average. Price action looks broadly range-bound.
Verrica Pharmaceuticals Inc.'s 2028 outlook centres on $6.98, within a $5.13 to $10.26 range. That is up +10% on the projected 2027 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, VRCA could reach as high as $9.51, with a base case around $6.23 and support toward $4.42 — roughly 0% from $6.26. Price action looks broadly range-bound.
Expect VRCA to range from $4.70 to $10.76 through 2030. The $6.83 average target implies a +9% move from current prices. That is up +10% on the projected 2029 average. A consolidation phase looks the most probable path here.
The VRCA price prediction for 2031 points to an average of $8.59 (low $5.74, high $13.93) — a potential gain of +37% on today's $6.26. Momentum favours further upside here.
In 2032, VRCA is projected to trade between $6.21 and $15.85, averaging $9.54 — a potential gain of +52% from today's $6.26. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Verrica Pharmaceuticals Inc.'s 2033 outlook centres on $10.92, within a $6.93 to $18.55 range. That is up +14% on the projected 2032 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2034, VRCA could reach as high as $18.11, with a base case around $10.44 and support toward $6.47 — roughly +67% from $6.26. Buyers look set to stay in control over this stretch.
Expect VRCA to range from $5.86 to $17.12 through 2035. The $9.69 average target implies a +55% move from current prices. That is -7% versus the projected 2034 average. Momentum favours further upside here.
The VRCA price prediction for 2040 points to an average of $16.25 (low $8.81, high $31.03) — a potential gain of +160% on today's $6.26. Buyers look set to stay in control over this stretch.
In 2050, VRCA is projected to trade between $10.36 and $49.15, averaging $23.02 — a potential gain of +268% from today's $6.26. That is up +42% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VRCA today (≈ 159.744409 VRCA) could be worth
$3,678.11
+$2,678.11 (+268%) by 2050 · US Dollar
Based on the average projected VRCA price of $23.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRCAwould be worth at today's price.
$1,000 invested in VRCA on Jul 10, 2025 (≈ 114.547543 VRCA) would be worth
$717.07
-$282.93 (-28.3%) today · 0.72× · US Dollar
Based on a VRCA entry price of $8.73 vs. today's $6.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.14 | $1,020.37 | +2.0% |
| 1 month ago | $5.75 | $1,088.7 | +8.9% |
| 3 months ago | $5.11 | $1,225.05 | +22.5% |
| 6 months ago | $8.02 | $780.55 | -21.9% |
| 1 year ago | $8.73 | $717.07 | -28.3% |
| All time (5.0y) ago | $109.8 | $57.01 | -94.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRCA forecast.
Our base-case forecast reaches $13.00 around 2040.
Implied market cap at $13.00: $223.32M
Forecasts show a neutral stance in the near term, with 2026 averaging $6.62 and a min of $4.38 and a max of $8.47 (ROI 0, sentiment NEUTRAL). By 2030 the average is projected at $7.38 with a min of $5.02 and a max of $11.76 (ROI 11.5, sentiment NEUTRAL). In the 2031–2035 window the outlook turns bullish, with 2031 average $9.40, 2032 $10.45, 2033 $11.98, 2034 $11.37 and 2035 $10.56.
Notable long-term milestones include 2040 average $17.97 (ROI 171.5) and 2050 average $25.55 (ROI 286), both with a bullish sentiment.
These figures are estimates and not guarantees. They imply potential upside and are subject to market and company-specific risks that could affect actual results.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $7.38, with a min of $5.02 and a max of $11.76; ROI 11.5 and sentiment NEUTRAL.
Near term the forecast is NEUTRAL through 2030, with a shift to BULLISH sentiment starting 2031 and continuing through 2050. The 2050 forecast shows an avg of $25.55 and ROI 286, indicating substantial long-term upside relative to the near term.
Yes. The 2030 forecast lists a max of $11.76, with an avg of $7.38 and a min of $5.02.
For 2026, min $4.38, avg $6.62, max $8.47; ROI 0; sentiment NEUTRAL.
2040: avg $17.97, min $9.50, max $34.86; ROI 171.5; sentiment BULLISH. 2050: avg $25.55, min $11.50, max $55.55; ROI 286; sentiment BULLISH.
Verrica Pharmaceuticals Inc. Community Discussion
0Share your Verrica Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.